A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This is a first-in-human, Phase 1/2, non-randomized, multi-centre, open-label clinical study
designed to investigate safety, tolerability, dosimetry, biodistribution, and PK of [225Ac]
FPI-1966, [111In]-FPI-1967, and vofatamab and the preliminary anti-tumour activity of
[225Ac]-FPI-1966 in participants with FGFR3-expressing advanced, inoperable, metastatic,
and/or recurrent solid tumours. Phase 1 consists of five multiple dose escalation cohorts.
Phase 2 consists of two tumour-specific cohorts and one basket cohort.